Feb 18, 2020
Stealth BioTherapeutics Announces Positive Results From Study to Evaluate Efficacy of Elamipretide in Barth Patients Compared to Natural History Control
Jan 08, 2020
Entrada Therapeutics Announces ENTR-501 for the Treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
Dec 20, 2019
NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study
Dec 20, 2019
Stealth BioTherapeutics Provides Update on Phase 3 Trial of Elamipretide in Primary Mitochondrial Myopathy
Nov 19, 2019
Stealth Biotherapeutics to Present at Jefferies 2019 London Healthcare Conference
Nov 15, 2019
Second Baby Born Using Maternal Spindle Transfer Method as Part of Clinical Study Conducted by the Institute of Life and Embryotools Scientific Team
Nov 11, 2019
Stealth Biotherapeutics to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019
Oct 17, 2019
Stealth BioTherapeutics Presents Data for Elamipretide on Cardiac Function in Barth Syndrome
Oct 16, 2019
Mitochondrial Disease Therapies Market, 2019-2030
Oct 07, 2019
Mitochondrial Disease Therapies Market, 2019-2030
Oct 07, 2019
Stealth BioTherapeutics Presents Data on SBT-272 in Neurodegeneration
Oct 01, 2019
Stealth Biotherapeutics to Present at the 2019 Cantor Global Healthcare Conference
Sep 20, 2019
Stealth BioTherapeutics to Attend Upcoming Investor Conferences
Sep 03, 2019
Stealth BioTherapeutics Announces Appointment of Robert Weiskopf as Chief Financial Officer
Aug 14, 2019
Stealth BioTherapeutics Reports First Half 2019 Financial Results And Recent Business Highlights
Jul 02, 2019
Stealth BioTherapeutics to Host KOL Breakfast Symposium on the Potential of Elamipretide in Orphan Mitochondrial Disorders
Apr 16, 2019
Stealth BioTherapeutics Announces Positive Results for Elamipretide in Barth Syndrome Open-Label Extension Trial
Apr 04, 2019
Stealth BioTherapeutics Reports Fiscal Year 2018 Financial Results and Recent Business Highlights
Mar 04, 2019
Stealth BioTherapeutics Announces Partial Exercise and Closing of Over-Allotment Option
Dec 10, 2018
Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Dry Age-Related Macular Degeneration with Geographic Atrophy